ArticleRNA biology2019
A novel human lncRNA SANT1
Open access · bronzeAbstract read
In one paragraph
Article in RNA biology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
1.4field-weighted citation impact, top 22% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 35 citations in OpenAlex.
- Multifaceted regulatory role of proline‑ and glutamine-rich splicing factor in tumors (Review).Molecular medicine reports · 2026Review
- Solute Carrier transporters in tumor metabolism and immune modulation: implications for therapy.Journal of translational medicine · 2026Review
- CCCTC-binding factor regulates splicing factor proline and glutamine-rich to promote malignant growth of osteosarcoma.American journal of translational research · 2025Article
- Article
- Quantitative estimates of the regulatory influence of long non-coding RNAs on global gene expression variation using TCGA breast cancer transcriptomic data.PLoS computational biology · 2024Article
- Induced pluripotent stem cell-derived extracellular vesicles overexpressing SFPQ protect retinal Müller cells against hypoxia-induced injury.Cell biology and toxicology · 2023Article
- Interactome of Long Non-Coding RNAs: Transcriptomic Expression Patterns and Shaping Cancer Cell Phenotypes.International journal of molecular sciences · 2023Review
- The splicing factor proline and glutamine rich promotes the growth of osteosarcoma via the c-Myc signaling pathway.American journal of cancer research · 2023Article
- Single-Cell Transcriptome Analysis Reveals Paraspeckles Expression in Osteosarcoma Tissues.Cancer informatics · 2022Article
- Bioinformatic Tools for the Analysis and Prediction of ncRNA Interactions.International journal of molecular sciences · 2021Review
- SFPQ promotes an oncogenic transcriptomic state in melanoma.Oncogene · 2021Article
- Regulation of MRP4 Expression by circHIPK3 via Sponging miR-124-3p/miR-4524-5p in Hepatocellular Carcinoma.Biomedicines · 2021Article
- Predicting lncRNA-Protein Interaction With Weighted Graph-Regularized Matrix Factorization.Frontiers in genetics · 2021Article
- Deep Insight Into Long Non-coding RNA and mRNA Transcriptome Profiling in HepG2 Cells Expressing Genotype IV Swine Hepatitis E Virus ORF3.Frontiers in veterinary science · 2021Article
- Review
- [Interaction between PSF and cytokeratin 18 mediates PSF relocation to cell membrane and maintains chemosensitivity of myeloid leukemia].Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2020Article
- Long non-coding RNA AFAP1-AS1 promotes cell growth and inhibits apoptosis by binding to specific proteins in germinal center B-cell-like diffuse large B-cell lymphoma.American journal of translational research · 2020Article
- The failure of DAC to induce OCT2 expression and its remission by hemoglobin-based nanocarriers under hypoxia in renal cell carcinoma.Theranostics · 2020Article
- Hes1 is associated with long non-coding RNAs in colorectal cancer.Annals of translational medicine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 2 institutions in 1 country.
Zhangzhao Gaoa Institute of Drug Metabolism and Pharmaceutical Analysis, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences , Zhejiang University , Hangzhou , China.
Mengjiao Chena Institute of Drug Metabolism and Pharmaceutical Analysis, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences , Zhejiang University , Hangzhou , China.
Xueke Tiana Institute of Drug Metabolism and Pharmaceutical Analysis, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences , Zhejiang University , Hangzhou , China.
Lu Chena Institute of Drug Metabolism and Pharmaceutical Analysis, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences , Zhejiang University , Hangzhou , China.
Le Chena Institute of Drug Metabolism and Pharmaceutical Analysis, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences , Zhejiang University , Hangzhou , China.
Xiaoli Zhenga Institute of Drug Metabolism and Pharmaceutical Analysis, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences , Zhejiang University , Hangzhou , China.
Hua Wangb Zhejiang Cancer Hospital , Hangzhou , China.
Jinchao Chenb Zhejiang Cancer Hospital , Hangzhou , China.
An Zhaob Zhejiang Cancer Hospital , Hangzhou , China.
Qingqing Yaoa Institute of Drug Metabolism and Pharmaceutical Analysis, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences , Zhejiang University , Hangzhou , China.
Qianying Zhua Institute of Drug Metabolism and Pharmaceutical Analysis, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences , Zhejiang University , Hangzhou , China.
Shengnan Jina Institute of Drug Metabolism and Pharmaceutical Analysis, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences , Zhejiang University , Hangzhou , China.
Haihong Hua Institute of Drug Metabolism and Pharmaceutical Analysis, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences , Zhejiang University , Hangzhou , China.
Su Zenga Institute of Drug Metabolism and Pharmaceutical Analysis, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences , Zhejiang University , Hangzhou , China.
Lushan Yua Institute of Drug Metabolism and Pharmaceutical Analysis, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences , Zhejiang University , Hangzhou , China.
Zhejiang University · CNZhejiang Cancer Hospital · CN
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Gene Expression Regulation, NeoplasticPromoter Regions, GeneticBase SequenceCarcinoma, Renal CellCell Line, TumorE2F1 Transcription FactorHEK293 CellsHistone Deacetylase 1HumansKidney NeoplasmsModels, BiologicalNucleic Acid ConformationOrganic Cation Transport ProteinsProtein BindingPTB-Associated Splicing FactorRNA, Long NoncodingE2F1 protein, humanE2F1 Transcription FactorHDAC1 protein, humanHistone Deacetylase 1Organic Cation Transport ProteinsPTB-Associated Splicing FactorRNA, Long NoncodingRNA, MessengerSLC47A2 protein, humanepigeneticslncRNArenal cell carcinomaSANT1SLC47A2
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.